April 25, 2016 / 7:22 AM / a year ago

BRIEF-Merck's phase iii tailor landmark study demonstrates significant benefits of Erbitux in combination with FOLFOX over FOLFOX alone

April 25 (Reuters) - Merck & Co Inc

* Says phase iii tailor landmark study demonstrates significant benefits of erbitux in combination with FOLFOX over FOLFOX alone

* Merck will work with relevant authorities to make Erbitux available for patients in China as a first-line treatment as soon as possible

* Phase iii tailor study met its primary endpoint of significantly increasing survival in patients with ras wild-type metastatic colorectal cancer

* Safety profile of Erbitux in tailor clinical trial was manageable,similar to observed in other trials, with no unexpected safety findings Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below